Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory Board
Neurocentria, Inc., a privately held late-stage biotechnology company developing novel therapies for neurodegenerative and neuropsychiatric disorders, has today announced that Dr. Thomas Südhof, Avram Goldstein Professor in Stanford University School of Medicine and an investigator of the Howard Hughes Medical Institute, has joined the company’s Scientific Advisory Board (SAB). Dr. Südhof’s appointment further strengthens the … Read more